In a comparison study 5 patients received both [131I]I-anti-CEA and [111In]In-anti-CEA in which [111In]In-anti-CEA could confirm 87% of the tumor lesions and [131I]I-anti-CEA only 53%. The gene discussed is CEACAM5; the disease is neoplasm.